US ANDA Approvals Soar, But Does FDA Need To Do More?
This article was originally published in PharmAsia News
Executive Summary
An industry consultant suggests that the US FDA’s Office of Generic Drugs has to boost its approval volume even higher if it wants to cut its increasing workload.
You may also be interested in...
Rare Cancer Development Consortium Moving Toward Target Selection
An upcoming public meeting will include a look at platforms before the first targets are chosen.
Stealth’s Elamipretide Gets US FDA Review, But Same Questions Linger
The Barth Syndrome candidate application will be reviewed by the FDA, but Stealth BioTherapeutics' CEO tells the Pink Sheet that the company still does not have clear guidance on how or whether it should gather additional clinical data.
Quick And Flexible Vaccine Approval Must Include Postmarket Simplicity, US FDA’s Kaslow Says
After making the COVID-19 vaccines available, multiple presentations based on age and vaccination status created confusion that likely hindered uptake, said OVRR Director David Kaslow.